Subjects was Grouped for Clinical Test on the Quadrivalent Meningococcal Conjugate Vaccine (MCV4) — Another Key Product of AIM Vaccine2023-03-17
Another key product — quadrivalent meningococcal conjugate vaccine (MCV4) has been developed independently by AIM Vaccine. On March 15, the clinical test was officially carried out at Yanshan Disease Prevention and Control Center in Yunnan Province and related subjects were grouped.
Bivalent Delta Omicron BA.5 mRNA COVID-19 Vaccine was Approved for Phase-III Clinical Test in Pakistan2023-03-14
Recently, AIM Vaccine’s bivalent Delta+ Omicron BA.5 mRNA COVID-19 vaccine under development was officially approved for Phase-III clinical test in Pakistan. The results of two clinical researches previously conducted in China indicate good safety, and the results of tests on live virus and antibody show that such vaccine under development can induce high-level neutralizing antibody against Delta, Omicron BA.5, BQ.1, and XBB variants of COVID-19 virus.